Literature DB >> 21057000

Survivin-induced Aurora-B kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development.

Tao Zhang1, Jeremy Z Fields, Lynn Opdenaker, Tomas Otevrel, Emi Masuda, Juan P Palazzo, Gerald A Isenberg, Scott D Goldstein, Marc Brand, Bruce M Boman.   

Abstract

APC mutations initiate most colorectal cancers (CRCs), but cellular mechanisms linking this to CRC pathology are unclear. We reported that wild-type APC in the colon down-regulates the anti-apoptotic protein survivin, and APC mutation up-regulates it, explaining why most CRCs display survivin overexpression and apoptosis inhibition. However, it does not explain another hallmark of CRC pathology--increased mitotic figures and cell proliferation. Because survivin activates aurora-B kinase (ABK) in vitro, catalyzing mitosis, we hypothesized that in normal colonic crypts, APC controls ABK activity, while in neoplastic APC-mutant crypts, ABK activity is up-regulated, increasing mitosis. We quantitatively mapped intracryptal distributions of survivin, ABK, and markers of activated downstream signaling and mitosis (INCENP, phospho-histone-H3, phospho-centromere-protein-A). In normal crypts, gradients for these markers, ABK:survivin:INCENP complexes, and ABK activity were highest in the lower crypt (inverse to the APC gradient). In neoplastic crypts that harbor APC mutations, proliferating (Ki-67+) cells and cells expressing survivin, ABK, and phospho-histone-H3 were distributed farther up the crypt. Hence, as cells migrate up neoplastic crypts, transitions between cell phenotypes (eg, from stem to proliferating) appear delayed. In CRC cell lines, increasing wild-type APC, inhibiting TCF-4, or decreasing survivin expression down-regulated ABK activity. Thus, APC mutation-induced up-regulation of the survivin/ABK cascade can explain delayed crypt cell maturation, expansion of proliferative cell populations (including mitotic figures), and promotion of colon tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057000      PMCID: PMC2993266          DOI: 10.2353/ajpath.2010.100047

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Survivin is required for stable checkpoint activation in taxol-treated HeLa cells.

Authors:  Ana Carvalho; Mar Carmena; Clara Sambade; William C Earnshaw; Sally P Wheatley
Journal:  J Cell Sci       Date:  2003-06-03       Impact factor: 5.285

2.  Correspondence re: T. Zhang et al., Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res., 61: 8664-8667, 2001.

Authors:  Maria Grazia Daidone; Aurora Costa; Milo Frattini; Debora Balestra; Lucio Bertario; Marco A Pierotti
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

3.  Isolation of normal human colonic mucosa: comparison of methods.

Authors:  D M Wildrick; P Lointier; D H Nichols; R Roll; B Quintanilla; B M Boman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-01       Impact factor: 2.416

4.  In vivo measurements in familial polyposis: kinetics and location of proliferating cells in colonic adenomas.

Authors:  C Lightdale; M Lipkin; E Deschner
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

5.  Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population.

Authors:  Bruce M Boman; Rhonda Walters; Jeremy Z Fields; Albert J Kovatich; Tao Zhang; Gerald A Isenberg; Scott D Goldstein; Juan P Palazzo
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  Apoptosis and APC in colorectal tumorigenesis.

Authors:  P J Morin; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  The APC gene product in normal and tumor cells.

Authors:  K J Smith; K A Johnson; T M Bryan; D E Hill; S Markowitz; J K Willson; C Paraskeva; G M Petersen; S R Hamilton; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Proliferation in human gastrointestinal epithelium using bromodeoxyuridine in vivo: data for different sites, proximity to a tumour, and polyposis coli.

Authors:  C S Potten; M Kellett; D A Rew; S A Roberts
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

9.  Chromatin remodeling and neuronal response: multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons.

Authors:  Claudia Crosio; Estelle Heitz; C David Allis; Emiliana Borrelli; Paolo Sassone-Corsi
Journal:  J Cell Sci       Date:  2003-12-15       Impact factor: 5.285

10.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.

Authors:  Claire Ditchfield; Victoria L Johnson; Anthony Tighe; Rebecca Ellston; Carolyn Haworth; Trevor Johnson; Andrew Mortlock; Nicholas Keen; Stephen S Taylor
Journal:  J Cell Biol       Date:  2003-04-28       Impact factor: 10.539

View more
  16 in total

1.  Multi-scale modeling of APC and [Formula: see text]-catenin regulation in the human colonic crypt.

Authors:  Brooks Emerick; Gilberto Schleiniger; Bruce M Boman
Journal:  J Math Biol       Date:  2018-01-04       Impact factor: 2.259

2.  Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population.

Authors:  Xia-Bin Li; Shi-Ning Li; Zhi-Hui Yang; Ling Cao; Fang-Lei Duan; Xing-Wang Sun
Journal:  DNA Cell Biol       Date:  2013-04-12       Impact factor: 3.311

3.  [The oncofetal gene survivin - a possible target gene for regenerative therapy concepts in cartilaginous tissue].

Authors:  P Lechler; M Handel; S Anders; S Balakrishnan; J Grifka
Journal:  Orthopade       Date:  2012-04       Impact factor: 1.087

4.  Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway.

Authors:  Liang Bo Zhu; Jian Jiang; Xiao Ping Zhu; Tao Fang Wang; Xuan Yin Chen; Qin Feng Luo; Yong Shu; Zhi Li Liu; Shan Hu Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  A kinetic model to study the regulation of β-catenin, APC, and Axin in the human colonic crypt.

Authors:  Brooks Emerick; Gilberto Schleiniger; Bruce M Boman
Journal:  J Math Biol       Date:  2017-03-07       Impact factor: 2.259

6.  Effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (β-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin).

Authors:  Sandra Regina Lepri; Leonardo Campos Zanelatto; Patrícia Benites Gonçalves da Silva; Daniele Sartori; Lucia Regina Ribeiro; Mario Sergio Mantovani
Journal:  Hum Cell       Date:  2014-01-04       Impact factor: 4.174

7.  The oncofetal gene survivin is re-expressed in osteoarthritis and is required for chondrocyte proliferation in vitro.

Authors:  Philipp Lechler; Sanjeevi Balakrishnan; Jens Schaumburger; Susanne Grässel; Clemens Baier; Joachim Grifka; Rainer H Straub; Tobias Renkawitz
Journal:  BMC Musculoskelet Disord       Date:  2011-07-05       Impact factor: 2.362

8.  Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis.

Authors:  Andreas Krieg; Thomas A Werner; Pablo E Verde; Nikolas H Stoecklein; Wolfram T Knoefel
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

Review 9.  An APC:WNT Counter-Current-Like Mechanism Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That Explains How APC Mutations Induce Proliferative Abnormalities That Drive Colon Cancer Development.

Authors:  Bruce M Boman; Jeremy Z Fields
Journal:  Front Oncol       Date:  2013-11-07       Impact factor: 6.244

10.  Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.

Authors:  Xiao Jiao Cheng; Jia Cheng Lin; Yan Fei Ding; Liming Zhu; Jing Ye; Shui Ping Tu
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.